Nuvalent, Inc. (NUVL) Stock Competitors & Peer Comparison
See (NUVL) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NUVL | $123.94 | +0.03% | 9.1B | -21.78 | -$5.69 | N/A |
| VRTX | $480.25 | -1.06% | 121.9B | 25.52 | $18.82 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $663.09 | -0.22% | 68.3B | 14.53 | $45.63 | +0.55% |
| ARGX | $876.25 | -0.16% | 54.5B | 79.08 | $11.08 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMD | $183.95 | -1.57% | 39.1B | -26.02 | -$7.07 | N/A |
| ALNY | $288.06 | -3.58% | 38.5B | 51.90 | $5.55 | N/A |
| RVMDW | $8.96 | -4.27% | 38.1B | -2.16 | -$4.15 | N/A |
| ONC | $303.96 | +1.76% | 32.5B | 68.00 | $4.47 | N/A |
Stock Comparison
NUVL vs VRTX Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, VRTX has a market cap of 121.9B. Regarding current trading prices, NUVL is priced at $123.94, while VRTX trades at $480.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas VRTX's P/E ratio is 25.52. In terms of profitability, NUVL's ROE is -0.43%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, NUVL is less volatile compared to VRTX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check VRTX's competition here
NUVL vs VRNA Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, NUVL is priced at $123.94, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas VRNA's P/E ratio is -102.80. In terms of profitability, NUVL's ROE is -0.43%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, NUVL is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check VRNA's competition here
NUVL vs REGN Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, REGN has a market cap of 68.3B. Regarding current trading prices, NUVL is priced at $123.94, while REGN trades at $663.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas REGN's P/E ratio is 14.53. In terms of profitability, NUVL's ROE is -0.43%, compared to REGN's ROE of +0.14%. Regarding short-term risk, NUVL is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check REGN's competition here
NUVL vs ARGX Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, ARGX has a market cap of 54.5B. Regarding current trading prices, NUVL is priced at $123.94, while ARGX trades at $876.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas ARGX's P/E ratio is 79.08. In terms of profitability, NUVL's ROE is -0.43%, compared to ARGX's ROE of +0.22%. Regarding short-term risk, NUVL is less volatile compared to ARGX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check ARGX's competition here
NUVL vs SGEN Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, NUVL is priced at $123.94, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas SGEN's P/E ratio is -57.19. In terms of profitability, NUVL's ROE is -0.43%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, NUVL is less volatile compared to SGEN. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check SGEN's competition here
NUVL vs RVMD Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, RVMD has a market cap of 39.1B. Regarding current trading prices, NUVL is priced at $123.94, while RVMD trades at $183.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas RVMD's P/E ratio is -26.02. In terms of profitability, NUVL's ROE is -0.43%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, NUVL is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check RVMD's competition here
NUVL vs ALNY Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, ALNY has a market cap of 38.5B. Regarding current trading prices, NUVL is priced at $123.94, while ALNY trades at $288.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas ALNY's P/E ratio is 51.90. In terms of profitability, NUVL's ROE is -0.43%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, NUVL is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check ALNY's competition here
NUVL vs RVMDW Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, RVMDW has a market cap of 38.1B. Regarding current trading prices, NUVL is priced at $123.94, while RVMDW trades at $8.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas RVMDW's P/E ratio is -2.16. In terms of profitability, NUVL's ROE is -0.43%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, NUVL is less volatile compared to RVMDW. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check RVMDW's competition here
NUVL vs ONC Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, ONC has a market cap of 32.5B. Regarding current trading prices, NUVL is priced at $123.94, while ONC trades at $303.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas ONC's P/E ratio is 68.00. In terms of profitability, NUVL's ROE is -0.43%, compared to ONC's ROE of +0.12%. Regarding short-term risk, NUVL is less volatile compared to ONC. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check ONC's competition here
NUVL vs MRNA Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, MRNA has a market cap of 26.6B. Regarding current trading prices, NUVL is priced at $123.94, while MRNA trades at $67.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas MRNA's P/E ratio is -8.22. In terms of profitability, NUVL's ROE is -0.43%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, NUVL is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check MRNA's competition here
NUVL vs ROIV Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, ROIV has a market cap of 24.8B. Regarding current trading prices, NUVL is priced at $123.94, while ROIV trades at $34.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas ROIV's P/E ratio is -35.47. In terms of profitability, NUVL's ROE is -0.43%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, NUVL is less volatile compared to ROIV. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check ROIV's competition here
NUVL vs INSM Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, INSM has a market cap of 23.7B. Regarding current trading prices, NUVL is priced at $123.94, while INSM trades at $109.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas INSM's P/E ratio is -18.98. In terms of profitability, NUVL's ROE is -0.43%, compared to INSM's ROE of -1.30%. Regarding short-term risk, NUVL is less volatile compared to INSM. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check INSM's competition here
NUVL vs INCY Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, INCY has a market cap of 22.8B. Regarding current trading prices, NUVL is priced at $123.94, while INCY trades at $114.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas INCY's P/E ratio is 15.35. In terms of profitability, NUVL's ROE is -0.43%, compared to INCY's ROE of +0.29%. Regarding short-term risk, NUVL is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check INCY's competition here
NUVL vs BNTX Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, BNTX has a market cap of 22.8B. Regarding current trading prices, NUVL is priced at $123.94, while BNTX trades at $90.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas BNTX's P/E ratio is -19.50. In terms of profitability, NUVL's ROE is -0.43%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, NUVL is less volatile compared to BNTX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check BNTX's competition here
NUVL vs UTHR Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, UTHR has a market cap of 22.7B. Regarding current trading prices, NUVL is priced at $123.94, while UTHR trades at $535.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas UTHR's P/E ratio is 19.77. In terms of profitability, NUVL's ROE is -0.43%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, NUVL is less volatile compared to UTHR. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check UTHR's competition here
NUVL vs BGNE Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, NUVL is priced at $123.94, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas BGNE's P/E ratio is -22.55. In terms of profitability, NUVL's ROE is -0.43%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, NUVL is less volatile compared to BGNE. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check BGNE's competition here
NUVL vs DNA-WT Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, NUVL is priced at $123.94, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, NUVL's ROE is -0.43%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, NUVL is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check DNA-WT's competition here
NUVL vs GMAB Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, GMAB has a market cap of 17.7B. Regarding current trading prices, NUVL is priced at $123.94, while GMAB trades at $28.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas GMAB's P/E ratio is 20.72. In terms of profitability, NUVL's ROE is -0.43%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, NUVL is less volatile compared to GMAB. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check GMAB's competition here
NUVL vs NBIX Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, NBIX has a market cap of 17.5B. Regarding current trading prices, NUVL is priced at $123.94, while NBIX trades at $174.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas NBIX's P/E ratio is 25.16. In terms of profitability, NUVL's ROE is -0.43%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, NUVL is less volatile compared to NBIX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check NBIX's competition here
NUVL vs ASND Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, ASND has a market cap of 16.5B. Regarding current trading prices, NUVL is priced at $123.94, while ASND trades at $265.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas ASND's P/E ratio is -109.60. In terms of profitability, NUVL's ROE is -0.43%, compared to ASND's ROE of -56.42%. Regarding short-term risk, NUVL is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check ASND's competition here
NUVL vs BBIO Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, BBIO has a market cap of 16.3B. Regarding current trading prices, NUVL is priced at $123.94, while BBIO trades at $83.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas BBIO's P/E ratio is -22.21. In terms of profitability, NUVL's ROE is -0.43%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, NUVL is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check BBIO's competition here
NUVL vs JAZZ Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, JAZZ has a market cap of 14.9B. Regarding current trading prices, NUVL is priced at $123.94, while JAZZ trades at $236.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas JAZZ's P/E ratio is 18.43. In terms of profitability, NUVL's ROE is -0.43%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, NUVL is less volatile compared to JAZZ. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check JAZZ's competition here
NUVL vs EXEL Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, EXEL has a market cap of 14.1B. Regarding current trading prices, NUVL is priced at $123.94, while EXEL trades at $56.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas EXEL's P/E ratio is 16.78. In terms of profitability, NUVL's ROE is -0.43%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, NUVL is less volatile compared to EXEL. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check EXEL's competition here
NUVL vs KRTX Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, NUVL is priced at $123.94, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas KRTX's P/E ratio is -28.09. In terms of profitability, NUVL's ROE is -0.43%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, NUVL is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check KRTX's competition here
NUVL vs MDGL Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, MDGL has a market cap of 12.2B. Regarding current trading prices, NUVL is priced at $123.94, while MDGL trades at $531.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas MDGL's P/E ratio is -41.48. In terms of profitability, NUVL's ROE is -0.43%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, NUVL is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check MDGL's competition here
NUVL vs SMMT Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, SMMT has a market cap of 11.9B. Regarding current trading prices, NUVL is priced at $123.94, while SMMT trades at $15.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas SMMT's P/E ratio is -9.56. In terms of profitability, NUVL's ROE is -0.43%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, NUVL is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check SMMT's competition here
NUVL vs AXSM Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, AXSM has a market cap of 11.7B. Regarding current trading prices, NUVL is priced at $123.94, while AXSM trades at $228.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas AXSM's P/E ratio is -59.60. In terms of profitability, NUVL's ROE is -0.43%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, NUVL is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check AXSM's competition here
NUVL vs BMRN Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, BMRN has a market cap of 11.4B. Regarding current trading prices, NUVL is priced at $123.94, while BMRN trades at $59.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas BMRN's P/E ratio is 28.46. In terms of profitability, NUVL's ROE is -0.43%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, NUVL is less volatile compared to BMRN. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check BMRN's competition here
NUVL vs RNAM Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, NUVL is priced at $123.94, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas RNAM's P/E ratio is -17.39. In terms of profitability, NUVL's ROE is -0.43%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, NUVL is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check RNAM's competition here
NUVL vs TECH Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, TECH has a market cap of 11.2B. Regarding current trading prices, NUVL is priced at $123.94, while TECH trades at $71.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas TECH's P/E ratio is 36.78. In terms of profitability, NUVL's ROE is -0.43%, compared to TECH's ROE of +0.05%. Regarding short-term risk, NUVL is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check TECH's competition here
NUVL vs KRYS Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, KRYS has a market cap of 10.7B. Regarding current trading prices, NUVL is priced at $123.94, while KRYS trades at $363.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas KRYS's P/E ratio is 48.59. In terms of profitability, NUVL's ROE is -0.43%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, NUVL is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check KRYS's competition here
NUVL vs ARWR Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, ARWR has a market cap of 10.4B. Regarding current trading prices, NUVL is priced at $123.94, while ARWR trades at $74.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas ARWR's P/E ratio is -34.47. In terms of profitability, NUVL's ROE is -0.43%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, NUVL is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check ARWR's competition here
NUVL vs CYTK Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, CYTK has a market cap of 10.2B. Regarding current trading prices, NUVL is priced at $123.94, while CYTK trades at $82.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas CYTK's P/E ratio is -14.11. In terms of profitability, NUVL's ROE is -0.43%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, NUVL is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check CYTK's competition here
NUVL vs ABVX Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, ABVX has a market cap of 10B. Regarding current trading prices, NUVL is priced at $123.94, while ABVX trades at $135.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas ABVX's P/E ratio is -71.12. In terms of profitability, NUVL's ROE is -0.43%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, NUVL is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check ABVX's competition here
NUVL vs RXDX Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, NUVL is priced at $123.94, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas RXDX's P/E ratio is -56.47. In terms of profitability, NUVL's ROE is -0.43%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, NUVL is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check RXDX's competition here
NUVL vs IONS Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, IONS has a market cap of 9.4B. Regarding current trading prices, NUVL is priced at $123.94, while IONS trades at $56.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas IONS's P/E ratio is -32.99. In terms of profitability, NUVL's ROE is -0.43%, compared to IONS's ROE of -0.59%. Regarding short-term risk, NUVL is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check IONS's competition here
NUVL vs CORT Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, CORT has a market cap of 9.2B. Regarding current trading prices, NUVL is priced at $123.94, while CORT trades at $85.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas CORT's P/E ratio is 245.43. In terms of profitability, NUVL's ROE is -0.43%, compared to CORT's ROE of +0.08%. Regarding short-term risk, NUVL is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check CORT's competition here
NUVL vs KYMR Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, KYMR has a market cap of 9.1B. Regarding current trading prices, NUVL is priced at $123.94, while KYMR trades at $110.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas KYMR's P/E ratio is -31.27. In terms of profitability, NUVL's ROE is -0.43%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, NUVL is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check KYMR's competition here
NUVL vs HALO Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, HALO has a market cap of 9B. Regarding current trading prices, NUVL is priced at $123.94, while HALO trades at $76.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas HALO's P/E ratio is 16.47. In terms of profitability, NUVL's ROE is -0.43%, compared to HALO's ROE of +1.26%. Regarding short-term risk, NUVL is less volatile compared to HALO. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check HALO's competition here
NUVL vs CRNX Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, CRNX has a market cap of 8.9B. Regarding current trading prices, NUVL is priced at $123.94, while CRNX trades at $83.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas CRNX's P/E ratio is -16.31. In terms of profitability, NUVL's ROE is -0.43%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, NUVL is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check CRNX's competition here
NUVL vs IMGN Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, NUVL is priced at $123.94, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas IMGN's P/E ratio is -111.55. In terms of profitability, NUVL's ROE is -0.43%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, NUVL is less volatile compared to IMGN. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check IMGN's competition here
NUVL vs ALKS Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, ALKS has a market cap of 8.6B. Regarding current trading prices, NUVL is priced at $123.94, while ALKS trades at $51.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas ALKS's P/E ratio is 54.60. In terms of profitability, NUVL's ROE is -0.43%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, NUVL is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check ALKS's competition here
NUVL vs TGTX Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, TGTX has a market cap of 8.4B. Regarding current trading prices, NUVL is priced at $123.94, while TGTX trades at $55.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas TGTX's P/E ratio is 18.90. In terms of profitability, NUVL's ROE is -0.43%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, NUVL is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check TGTX's competition here
NUVL vs BPMC Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, NUVL is priced at $123.94, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas BPMC's P/E ratio is -51.58. In terms of profitability, NUVL's ROE is -0.43%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, NUVL is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check BPMC's competition here
NUVL vs PTGX Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, PTGX has a market cap of 8.4B. Regarding current trading prices, NUVL is priced at $123.94, while PTGX trades at $129.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas PTGX's P/E ratio is -71.76. In terms of profitability, NUVL's ROE is -0.43%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, NUVL is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check PTGX's competition here
NUVL vs APGE Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, NUVL is priced at $123.94, while APGE trades at $133.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas APGE's P/E ratio is -30.91. In terms of profitability, NUVL's ROE is -0.43%, compared to APGE's ROE of -0.33%. Regarding short-term risk, NUVL is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check APGE's competition here
NUVL vs PCVX Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, PCVX has a market cap of 8.2B. Regarding current trading prices, NUVL is priced at $123.94, while PCVX trades at $57.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas PCVX's P/E ratio is -8.29. In terms of profitability, NUVL's ROE is -0.43%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, NUVL is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check PCVX's competition here
NUVL vs CERE Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, NUVL is priced at $123.94, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas CERE's P/E ratio is -16.47. In terms of profitability, NUVL's ROE is -0.43%, compared to CERE's ROE of -0.72%. Regarding short-term risk, NUVL is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check CERE's competition here
NUVL vs IBRX Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, IBRX has a market cap of 8.2B. Regarding current trading prices, NUVL is priced at $123.94, while IBRX trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas IBRX's P/E ratio is -24.34. In terms of profitability, NUVL's ROE is -0.43%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, NUVL is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check IBRX's competition here
NUVL vs IMVT Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, IMVT has a market cap of 7.9B. Regarding current trading prices, NUVL is priced at $123.94, while IMVT trades at $38.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas IMVT's P/E ratio is -14.49. In terms of profitability, NUVL's ROE is -0.43%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, NUVL is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check IMVT's competition here
NUVL vs MTSR Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, NUVL is priced at $123.94, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas MTSR's P/E ratio is -23.58. In terms of profitability, NUVL's ROE is -0.43%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, NUVL is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check MTSR's competition here
NUVL vs RYTM Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, RYTM has a market cap of 7.4B. Regarding current trading prices, NUVL is priced at $123.94, while RYTM trades at $107.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas RYTM's P/E ratio is -34.34. In terms of profitability, NUVL's ROE is -0.43%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, NUVL is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check RYTM's competition here
NUVL vs MRUS Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, NUVL is priced at $123.94, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas MRUS's P/E ratio is -17.05. In terms of profitability, NUVL's ROE is -0.43%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, NUVL is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check MRUS's competition here
NUVL vs PTCT Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, PTCT has a market cap of 6.7B. Regarding current trading prices, NUVL is priced at $123.94, while PTCT trades at $81.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas PTCT's P/E ratio is -34.91. In terms of profitability, NUVL's ROE is -0.43%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, NUVL is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check PTCT's competition here
NUVL vs ACLX Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, NUVL is priced at $123.94, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas ACLX's P/E ratio is -28.27. In terms of profitability, NUVL's ROE is -0.43%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, NUVL is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check ACLX's competition here
NUVL vs PRAX Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, PRAX has a market cap of 6.7B. Regarding current trading prices, NUVL is priced at $123.94, while PRAX trades at $314.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas PRAX's P/E ratio is -23.53. In terms of profitability, NUVL's ROE is -0.43%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, NUVL is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check PRAX's competition here
NUVL vs RETA Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, NUVL is priced at $123.94, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas RETA's P/E ratio is -66.29. In terms of profitability, NUVL's ROE is -0.43%, compared to RETA's ROE of +0.47%. Regarding short-term risk, NUVL and RETA have similar daily volatility (0.08).Check RETA's competition here
NUVL vs SRRK Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, SRRK has a market cap of 6.6B. Regarding current trading prices, NUVL is priced at $123.94, while SRRK trades at $54.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas SRRK's P/E ratio is -15.24. In terms of profitability, NUVL's ROE is -0.43%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, NUVL is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check SRRK's competition here
NUVL vs COGT Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, COGT has a market cap of 6.4B. Regarding current trading prices, NUVL is priced at $123.94, while COGT trades at $37.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas COGT's P/E ratio is -17.75. In terms of profitability, NUVL's ROE is -0.43%, compared to COGT's ROE of -0.83%. Regarding short-term risk, NUVL is less volatile compared to COGT. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check COGT's competition here
NUVL vs CGON Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, CGON has a market cap of 6.4B. Regarding current trading prices, NUVL is priced at $123.94, while CGON trades at $72.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas CGON's P/E ratio is -31.12. In terms of profitability, NUVL's ROE is -0.43%, compared to CGON's ROE of -0.23%. Regarding short-term risk, NUVL is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check CGON's competition here
NUVL vs LQDA Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, LQDA has a market cap of 6.3B. Regarding current trading prices, NUVL is priced at $123.94, while LQDA trades at $71.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas LQDA's P/E ratio is 508.64. In terms of profitability, NUVL's ROE is -0.43%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, NUVL is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check LQDA's competition here
NUVL vs CNTA Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, NUVL is priced at $123.94, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas CNTA's P/E ratio is -22.63. In terms of profitability, NUVL's ROE is -0.43%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, NUVL is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check CNTA's competition here
NUVL vs LGND Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, LGND has a market cap of 6.2B. Regarding current trading prices, NUVL is priced at $123.94, while LGND trades at $309.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas LGND's P/E ratio is 37.08. In terms of profitability, NUVL's ROE is -0.43%, compared to LGND's ROE of +0.16%. Regarding short-term risk, NUVL is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check LGND's competition here
NUVL vs MIRM Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, MIRM has a market cap of 6B. Regarding current trading prices, NUVL is priced at $123.94, while MIRM trades at $119.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas MIRM's P/E ratio is -8.75. In terms of profitability, NUVL's ROE is -0.43%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, NUVL is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check MIRM's competition here
NUVL vs BLTE Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, BLTE has a market cap of 5.9B. Regarding current trading prices, NUVL is priced at $123.94, while BLTE trades at $147.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas BLTE's P/E ratio is -78.63. In terms of profitability, NUVL's ROE is -0.43%, compared to BLTE's ROE of -0.18%. Regarding short-term risk, NUVL is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check BLTE's competition here
NUVL vs SYRE Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, SYRE has a market cap of 5.7B. Regarding current trading prices, NUVL is priced at $123.94, while SYRE trades at $93.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas SYRE's P/E ratio is -45.06. In terms of profitability, NUVL's ROE is -0.43%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, NUVL is less volatile compared to SYRE. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check SYRE's competition here
NUVL vs CDTX Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, NUVL is priced at $123.94, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas CDTX's P/E ratio is -19.77. In terms of profitability, NUVL's ROE is -0.43%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, NUVL is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check CDTX's competition here
NUVL vs ERAS Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, ERAS has a market cap of 5.6B. Regarding current trading prices, NUVL is priced at $123.94, while ERAS trades at $17.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas ERAS's P/E ratio is -40.68. In terms of profitability, NUVL's ROE is -0.43%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, NUVL is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check ERAS's competition here
NUVL vs ABCM Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, NUVL is priced at $123.94, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, NUVL's ROE is -0.43%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, NUVL and ABCM have similar daily volatility (0.08).Check ABCM's competition here
NUVL vs ISEE Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, NUVL is priced at $123.94, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas ISEE's P/E ratio is -22.44. In terms of profitability, NUVL's ROE is -0.43%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, NUVL is less volatile compared to ISEE. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check ISEE's competition here
NUVL vs XENE Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, XENE has a market cap of 5.3B. Regarding current trading prices, NUVL is priced at $123.94, while XENE trades at $67.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas XENE's P/E ratio is -14.41. In terms of profitability, NUVL's ROE is -0.43%, compared to XENE's ROE of -0.49%. Regarding short-term risk, NUVL is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check XENE's competition here
NUVL vs APLS Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, NUVL is priced at $123.94, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas APLS's P/E ratio is 38.35. In terms of profitability, NUVL's ROE is -0.43%, compared to APLS's ROE of +0.40%. Regarding short-term risk, NUVL is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check APLS's competition here
NUVL vs TVTX Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, TVTX has a market cap of 5.2B. Regarding current trading prices, NUVL is priced at $123.94, while TVTX trades at $56.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas TVTX's P/E ratio is -255.86. In terms of profitability, NUVL's ROE is -0.43%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, NUVL is less volatile compared to TVTX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check TVTX's competition here
NUVL vs CELC Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, CELC has a market cap of 5.1B. Regarding current trading prices, NUVL is priced at $123.94, while CELC trades at $103.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas CELC's P/E ratio is -26.61. In terms of profitability, NUVL's ROE is -0.43%, compared to CELC's ROE of -2.45%. Regarding short-term risk, NUVL is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check CELC's competition here
NUVL vs CRSP Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, CRSP has a market cap of 4.9B. Regarding current trading prices, NUVL is priced at $123.94, while CRSP trades at $50.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas CRSP's P/E ratio is -9.91. In terms of profitability, NUVL's ROE is -0.43%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, NUVL is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check CRSP's competition here
NUVL vs CAI Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, CAI has a market cap of 4.8B. Regarding current trading prices, NUVL is priced at $123.94, while CAI trades at $17.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas CAI's P/E ratio is -93.84. In terms of profitability, NUVL's ROE is -0.43%, compared to CAI's ROE of +0.06%. Regarding short-term risk, NUVL is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check CAI's competition here
NUVL vs TERN Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, NUVL is priced at $123.94, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas TERN's P/E ratio is -51.41. In terms of profitability, NUVL's ROE is -0.43%, compared to TERN's ROE of -0.20%. Regarding short-term risk, NUVL is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check TERN's competition here
NUVL vs LEGN Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, LEGN has a market cap of 4.8B. Regarding current trading prices, NUVL is priced at $123.94, while LEGN trades at $25.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas LEGN's P/E ratio is -37.87. In terms of profitability, NUVL's ROE is -0.43%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, NUVL is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check LEGN's competition here
NUVL vs DFTX Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, DFTX has a market cap of 4.8B. Regarding current trading prices, NUVL is priced at $123.94, while DFTX trades at $43.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas DFTX's P/E ratio is N/A. In terms of profitability, NUVL's ROE is -0.43%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, NUVL is less volatile compared to DFTX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check DFTX's competition here
NUVL vs MANE Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, MANE has a market cap of 4.6B. Regarding current trading prices, NUVL is priced at $123.94, while MANE trades at $110.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas MANE's P/E ratio is -35.03. In terms of profitability, NUVL's ROE is -0.43%, compared to MANE's ROE of -0.84%. Regarding short-term risk, NUVL is less volatile compared to MANE. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check MANE's competition here
NUVL vs FOLD Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, NUVL is priced at $123.94, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas FOLD's P/E ratio is -161.00. In terms of profitability, NUVL's ROE is -0.43%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, NUVL is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check FOLD's competition here
NUVL vs AKRO Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, NUVL is priced at $123.94, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas AKRO's P/E ratio is -14.57. In terms of profitability, NUVL's ROE is -0.43%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, NUVL is less volatile compared to AKRO. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check AKRO's competition here
NUVL vs ALPN Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, NUVL is priced at $123.94, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas ALPN's P/E ratio is -101.52. In terms of profitability, NUVL's ROE is -0.43%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, NUVL is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check ALPN's competition here
NUVL vs EWTX Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, EWTX has a market cap of 4.4B. Regarding current trading prices, NUVL is priced at $123.94, while EWTX trades at $41.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas EWTX's P/E ratio is -24.86. In terms of profitability, NUVL's ROE is -0.43%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, NUVL is less volatile compared to EWTX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check EWTX's competition here
NUVL vs VKTX Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, VKTX has a market cap of 4.4B. Regarding current trading prices, NUVL is priced at $123.94, while VKTX trades at $38.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas VKTX's P/E ratio is -9.21. In terms of profitability, NUVL's ROE is -0.43%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, NUVL is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check VKTX's competition here
NUVL vs ACAD Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, ACAD has a market cap of 4.4B. Regarding current trading prices, NUVL is priced at $123.94, while ACAD trades at $25.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas ACAD's P/E ratio is 12.50. In terms of profitability, NUVL's ROE is -0.43%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, NUVL is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check ACAD's competition here
NUVL vs OPT Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, NUVL is priced at $123.94, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas OPT's P/E ratio is -1.52. In terms of profitability, NUVL's ROE is -0.43%, compared to OPT's ROE of +1.18%. Regarding short-term risk, NUVL is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check OPT's competition here
NUVL vs DNLI Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, DNLI has a market cap of 4.2B. Regarding current trading prices, NUVL is priced at $123.94, while DNLI trades at $26.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas DNLI's P/E ratio is -9.19. In terms of profitability, NUVL's ROE is -0.43%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, NUVL is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check DNLI's competition here
NUVL vs NAMSW Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, NAMSW has a market cap of 4.1B. Regarding current trading prices, NUVL is priced at $123.94, while NAMSW trades at $24.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas NAMSW's P/E ratio is -13.76. In terms of profitability, NUVL's ROE is -0.43%, compared to NAMSW's ROE of -0.30%. Regarding short-term risk, NUVL is less volatile compared to NAMSW. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check NAMSW's competition here
NUVL vs DNTH Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, DNTH has a market cap of 4.1B. Regarding current trading prices, NUVL is priced at $123.94, while DNTH trades at $98.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas DNTH's P/E ratio is -23.88. In terms of profitability, NUVL's ROE is -0.43%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, NUVL is less volatile compared to DNTH. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check DNTH's competition here
NUVL vs MRTX Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, NUVL is priced at $123.94, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas MRTX's P/E ratio is -4.82. In terms of profitability, NUVL's ROE is -0.43%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, NUVL is less volatile compared to MRTX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check MRTX's competition here
NUVL vs DYN Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, DYN has a market cap of 3.9B. Regarding current trading prices, NUVL is priced at $123.94, while DYN trades at $23.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas DYN's P/E ratio is -7.34. In terms of profitability, NUVL's ROE is -0.43%, compared to DYN's ROE of -0.58%. Regarding short-term risk, NUVL is less volatile compared to DYN. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check DYN's competition here
NUVL vs NAMS Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, NAMS has a market cap of 3.9B. Regarding current trading prices, NUVL is priced at $123.94, while NAMS trades at $33.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas NAMS's P/E ratio is -20.93. In terms of profitability, NUVL's ROE is -0.43%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, NUVL is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check NAMS's competition here
NUVL vs CPRX Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, NUVL is priced at $123.94, while CPRX trades at $31.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas CPRX's P/E ratio is 11.32. In terms of profitability, NUVL's ROE is -0.43%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, NUVL is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check CPRX's competition here
NUVL vs RYZB Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, NUVL is priced at $123.94, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas RYZB's P/E ratio is -57.86. In terms of profitability, NUVL's ROE is -0.43%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, NUVL is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check RYZB's competition here
NUVL vs CBAY Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, NUVL is priced at $123.94, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas CBAY's P/E ratio is -32.81. In terms of profitability, NUVL's ROE is -0.43%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, NUVL is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check CBAY's competition here
NUVL vs TLX Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, TLX has a market cap of 3.7B. Regarding current trading prices, NUVL is priced at $123.94, while TLX trades at $10.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas TLX's P/E ratio is -596.20. In terms of profitability, NUVL's ROE is -0.43%, compared to TLX's ROE of -0.02%. Regarding short-term risk, NUVL is less volatile compared to TLX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check TLX's competition here
NUVL vs ELVN Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, ELVN has a market cap of 3.6B. Regarding current trading prices, NUVL is priced at $123.94, while ELVN trades at $50.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas ELVN's P/E ratio is -30.46. In terms of profitability, NUVL's ROE is -0.43%, compared to ELVN's ROE of -0.21%. Regarding short-term risk, NUVL is less volatile compared to ELVN. This indicates potentially lower risk in terms of short-term price fluctuations for NUVL.Check ELVN's competition here
NUVL vs SWTX Comparison July 2026
NUVL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVL stands at 9.1B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, NUVL is priced at $123.94, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVL currently has a P/E ratio of -21.78, whereas SWTX's P/E ratio is -13.78. In terms of profitability, NUVL's ROE is -0.43%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, NUVL is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for NUVL.Check SWTX's competition here